Mainboard IPOs - PhysicsWallah is launching an IPO worth Rs 3,480 crore with a price band of Rs 103–109 per share, opening on November 11 and closing on November 13, aiming to enhance its technology platform and expand learning centres [1][8] - Tenneco Clean Air India, a subsidiary of Tenneco Inc., is offering an IPO of Rs 3,600 crore entirely as an offer for sale, with a price band of Rs 378–397 per share, opening on November 12 and closing on November 14 [2][8] - Emmvee Photovoltaic Power is set to open its IPO of Rs 2,900 crore on November 11, priced between Rs 206–217 per share, focusing on India's clean energy sector [5][8] SME IPOs - Mahamaya Lifesciences plans to raise Rs 70.44 crore through its IPO, opening on November 11 and closing on November 13, with a price band of Rs 108–114 per share [6][9] - Workmates Core2Cloud Solution is launching an IPO of Rs 69.84 crore, opening on November 11 and closing on November 13, with a price range of Rs 200–204 per share, specializing in cloud computing and cybersecurity [7][9] Market Overview - The upcoming week will see five IPOs, three from the mainboard and two from the SME segment, with cumulative fundraising exceeding Rs 10,000 crore, testing market liquidity and sentiment [8]

Financial Highlights - Q3 2025 net income attributable to IEP was $287 million, or $049 per depositary unit, compared to $22 million, or $005 per depositary unit, for Q3 2024[6] - Q3 2025 Adjusted EBITDA attributable to IEP was $383 million compared to $183 million for Q3 2024[6] - Indicative net asset value as of September 30, 2025, was approximately $38 billion, an increase of $567 million compared to June 30, 2025[6] - IEP declares third quarter distribution of $050 per depositary unit[6] Segment Performance - Energy segment net income was $258 million in Q3 2025, compared to a loss of $88 million in Q3 2024[9] - Energy segment Adjusted EBITDA was $409 million in Q3 2025, compared to a loss of $38 million in Q3 2024[9] - Investment segment returns were negative 05% for Q3 2025[13, 15] - Automotive Services revenue was $366 million, up $11 million when compared to Q3 2024[25] - Food Packaging Q3 2025 Adjusted EBITDA attributable to IEP decreased by $8 million compared to prior year quarter[32]

Core Insights - Cwm LLC increased its holdings in Supernus Pharmaceuticals by 92.4% in Q2, owning 3,080 shares valued at $97,000 [2] - Other institutional investors also adjusted their stakes, with notable increases from GAMMA Investing LLC (116.7% increase) and State of Wyoming (58.8% increase) [3] - Insider trading activity included CEO Jack A. Khattar selling 140,000 shares for approximately $5.88 million, reducing his ownership by 11.96% [4] Institutional Holdings - Cwm LLC's investment grew to 3,080 shares after acquiring an additional 1,479 shares in Q2 [2] - Caitong International Asset Management and BI Asset Management both acquired new stakes in Q1, valued at approximately $41,000 and $46,000 respectively [3] - State of Wyoming increased its holdings to 4,754 shares, worth $156,000 after buying 1,761 additional shares [3] Insider Activity - CEO Jack A. Khattar sold 140,000 shares at an average price of $42.02, totaling $5,882,800, leaving him with 1,030,183 shares valued at approximately $43.29 million [4] - SVP Frank Mottola sold 14,000 shares at an average price of $44.51, resulting in a total transaction of $623,140 and a 47.46% decrease in ownership [4] - In the last three months, insiders sold 362,741 shares valued at $16.39 million, with insiders owning 8.80% of the stock [4] Stock Performance - Supernus Pharmaceuticals shares opened at $55.13, with a market capitalization of $3.09 billion and a P/E ratio of 47.94 [5] - The stock has a 1-year low of $29.16 and a high of $57.65, with a fifty-day moving average of $48.02 [5] Analyst Ratings - Bank of America initiated coverage with a "buy" rating and a target price of $65.00 [6] - Cantor Fitzgerald raised its price target from $46.00 to $63.00, maintaining an "overweight" rating [6] - The consensus rating for Supernus Pharmaceuticals is "Buy" with an average target price of $63.25 [6] Company Overview - Supernus Pharmaceuticals focuses on developing and commercializing products for central nervous system diseases [8] - Key products include Trokendi XR for epilepsy and migraine prophylaxis, and Oxtellar XR for partial onset seizures [8]

Core Viewpoint - Collegium Pharmaceutical (COLL) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling actions that affect stock prices [4]. Company Performance and Outlook - The upgrade for Collegium Pharmaceutical reflects an improvement in its underlying business, suggesting that investors may push the stock price higher due to this positive trend [5][10]. - The Zacks Consensus Estimate for Collegium Pharmaceutical indicates expected earnings of $7.03 per share for the fiscal year ending December 2025, with a 1.8% increase in estimates over the past three months [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, positioning Collegium Pharmaceutical among the best candidates for potential market-beating returns [9][10].

Core Insights - CROSSJECT reported its financial results for the first half of 2025, highlighting progress in regulatory activities and financial performance [3][4][9]. Financial Performance - The company recorded revenues of €8,038,000 for H1 2025, an increase from €5,766,000 in H1 2024 [13]. - R&D reimbursements from BARDA rose significantly to €6,584,000 in H1 2025, compared to €3,064,000 in H1 2024, reflecting increased R&D activities [13][19]. - The operating loss improved to €5,139,000 in H1 2025 from €6,719,000 in H1 2024, indicating better cost management [14]. - The net loss for the period was €4,868,000, down from €6,402,000 in the same period last year [14]. Regulatory and Development Activities - CROSSJECT continued its regulatory efforts with BARDA to obtain Emergency Use Authorization (EUA) for ZEPIZURE® in the U.S. [4][9]. - The company produced validation batches in collaboration with its CDMO partner EUROFINS, which are part of the EUA dossier [5]. - In September 2025, CROSSJECT secured an €11.3 million extension of R&D funding from the U.S. government [5]. Production and Innovation - The company finalized the development of the ZENEO® Nest module to enhance aseptic filling operations, preparing for increased production volumes [7]. - CROSSJECT maintained a cash position of €6.3 million as of June 30, 2025, down from €7.0 million at the end of 2024, reflecting effective resource management [9]. Strategic Collaborations - The company strengthened its marketing strategy for ZEPIZURE® by collaborating with opinion leaders in epilepsy and emergency medicine [8]. - In preparation for potential FDA inspections, BARDA conducted mock audits during the summer [10].

Core Insights - Santhera Pharmaceuticals reported a significant increase in total revenue by 70% to CHF 24 million for the first half of 2025, driven by strong sales of AGAMREE and growing royalty revenues [5][23][24] - The company is advancing the global rollout of AGAMREE, particularly in the US, Germany, Austria, and the UK, with expectations for continued growth in sales and market share [3][6][14] - Santhera has secured additional financing of approximately CHF 20 million to support increased product demand and global launches, maintaining a cash-flow break-even guidance for mid-2026 [21][31] Financial Performance - Total revenue increased to CHF 24 million from CHF 14.1 million in H1 2024, with product sales rising 76% to CHF 11.6 million [5][23][24] - Royalties from licensing partners surged to CHF 5.4 million, a 500% increase compared to CHF 0.9 million in H1 2024, indicating strong growth in the US and China [5][24] - Operating loss widened to CHF 35.4 million from CHF 17.7 million in H1 2024, primarily due to a one-time milestone payment of USD 25 million [31][28] Market Expansion - AGAMREE has achieved over 40% market penetration among steroid-using DMD patients in Germany, with Austria exceeding 50% market share [6][7] - The UK market has positively contributed following the nationwide launch in April 2025, supported by favorable NICE guidance [8] - Santhera is actively pursuing pricing and reimbursement discussions in Spain, Italy, and the Nordic regions, with launches expected from Q4 2025 to Q1 2026 [10][11][12] Strategic Initiatives - The company is focusing on expanding its distribution agreements across multiple regions, including five Gulf Cooperation Council countries, India, and Türkiye [15][17] - Santhera plans to present long-term clinical outcomes from the GUARDIAN study in early Q4 2025, which may further support AGAMREE's market position [18] - The company is not planning near-term investments in additional indication expansions for AGAMREE but is looking to leverage partnerships for future studies [19] Leadership and Governance - Santhera appointed Catherine Isted as CFO in February 2025 and Dr. Melanie Rolli to the Board in May 2025, enhancing its leadership team with experienced professionals [20]

Core Insights - Santhera Pharmaceuticals has signed an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. for the distribution and promotion of AGAMREE® (vamorolone) in Turkey for treating Duchenne muscular dystrophy (DMD) in patients aged four and older [1][2] - The supply and sales by GEN are expected to commence in the first half of 2026, starting with named patient sales followed by commercial sales [1] - Santhera will receive a small upfront payment and an ongoing percentage of net sales as per previous agreements [1] Company Overview - Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on developing innovative medicines for rare neuromuscular diseases with high unmet medical needs [7] - AGAMREE® (vamorolone) is a dissociative steroid with a novel mode of action, approved in multiple regions including the U.S., EU, UK, China, and Hong Kong for the treatment of DMD [7][9] - The company has out-licensed rights to AGAMREE for North America and certain Southeast Asian countries [9] Product Information - AGAMREE is designed to bind to the same receptor as glucocorticoids but modifies its downstream activity, potentially dissociating efficacy from steroid safety concerns [3] - In the pivotal VISION-DMD study, AGAMREE met the primary endpoint of Time to Stand (TTSTAND) velocity versus placebo with a p-value of 0.002 at 24 weeks, demonstrating a good safety and tolerability profile [4] - Unlike corticosteroids, AGAMREE shows no restriction of growth and has no negative effects on bone metabolism [5] Partner Company Overview - Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. is Turkey's leading specialty pharmaceutical company, focusing on innovative therapies for neurological and neuromuscular disorders since 1998 [10] - GEN has a GMP-certified facility and invests in original drug development through dedicated R&D centers [10]

Financial Results - Q2 2025 net loss attributable to IEP was $165 million, compared to a net loss of $331 million for Q2 2024[6] - Q2 2025 Adjusted EBITDA loss attributable to IEP was $43 million, compared to an Adjusted EBITDA loss of $155 million for Q2 2024[6] - Indicative net asset value as of June 30, 2025, was approximately $3.3 billion, an increase of $252 million compared to March 31, 2025[6] - The company declares a second quarter distribution of $0.50 per depositary unit[6] Segment Performance - Energy segment: Adjusted EBITDA decreased by $127 million to a loss of $24 million for Q2 2025 compared to $103 million in Q2 2024[17, 20] - Automotive segment: Adjusted EBITDA decreased $27 million for Q2 2025 compared to Q2 2024, impacted by higher labor costs and operating expenses[23, 24] - Investment segment: Returns of negative 0.5% for Q2 2025[12, 14] - All Other Segments: Q2 2025 Adjusted EBITDA attributable to IEP was $17 million compared to $28 million for Q2 2024[31] Energy Segment Details - Refining margin for Q2 2025 was $2.21 per throughput barrel, compared to $10.94 during Q2 2024[17, 20] - Renewable margin for Q2 2025 was $0.38 per vegetable oil throughput gallon, compared to $0.43 in Q2 2024[17, 20] - Q2 2025 average realized gate prices for UAN increased by 18% to $317 per ton and ammonia increased by 14% to $593 per ton when compared to Q2 2024[17, 19]

Company Overview - As of March 31, 2025, Carl Icahn and his affiliates owned approximately 86% of IEP's outstanding depositary units[7,8] - As of May 15, 2025, IEP has a $200 annualized distribution, which is a 207% yield[7] - As of March 31, 2025, IEP has liquidity through its investment in the Investment Funds of approximately $25 billion[7] Financial Performance (LTM March 31, 2025) - Investment segment assets were $3850 million, with a net loss attributable to IEP of $333 million[7] - Energy segment assets were $4722 million, with net sales of $7393 million and a net loss attributable to IEP of $153 million[7] - Automotive segment assets were $1881 million, with net sales of $1470 million and a net loss attributable to IEP of $34 million[7] - Food Packaging segment assets were $434 million, with net sales of $397 million and a net loss attributable to IEP of $20 million[7] - Real Estate segment assets were $512 million, with net sales of $95 million and a net loss attributable to IEP of $6 million[7] - Home Fashion segment assets were $220 million, with net sales of $181 million and a net loss attributable to IEP of $9 million[7] - Pharma segment assets were $274 million, with net sales of $107 million and a net income attributable to IEP of $6 million[7]

Financial Performance - Icahn Enterprises L P reported a net loss attributable to IEP of $422 million for Q1 2025, compared to a net loss of $38 million for Q1 2024[6] - Adjusted EBITDA loss attributable to IEP was $287 million for Q1 2025, a decrease compared to an Adjusted EBITDA of $134 million for Q1 2024[6] - The Investment segment reported a net loss attributable to IEP of $224 million for Q1 2025, compared to a net loss of $23 million in Q1 2024[9, 12] - The Energy segment experienced a net loss attributable to IEP of $86 million in Q1 2025, compared to a net income of $49 million in Q1 2024[9] - The Automotive segment had a net loss of $27 million in Q1 2025, compared to a net loss of $9 million in Q1 2024[9] Segment Highlights - The Investment segment's Funds had a net long notional exposure of 20% as of March 31, 2025, with returns of negative 8 4% for Q1 2025[12] - The Energy segment's consolidated Adjusted EBITDA decreased by $264 million to a loss of $61 million for Q1 2025, compared to $203 million in Q1 2024[15, 18] - Automotive Services revenue decreased by $23 million primarily due to reduced pricing and a shift of consumer behavior toward lower priced offerings[23] - Aftermarket Parts revenue in the Automotive segment decreased by $11 million due to the exit of the Aftermarket Parts business, completed in Q1 2025[22, 23] - Food Packaging Q1 2025 Adjusted EBITDA attributable to IEP decreased by $6 million compared to prior year quarter primarily due to lower price and higher manufacturing inefficiencies[26, 30] Liquidity and Net Asset Value - As of March 31, 2025, the indicative net asset value was approximately $3 billion, a decrease of $336 million compared to December 31, 2024[6] - Total Holding Company liquid assets were $3 781 billion as of March 31, 2025, including $1 318 billion in cash and cash equivalents and $2 463 billion in Investment Funds[32]